Ovarian Cancer Drugs Market Size, Share & Trends Analysis Report Forecast Period 2024-2031.
Ovarian Cancer Drugs Market Size, Share & Trends Analysis Report Forecast Period 2024-2031.
Blog Article
Ovarian cancer drugs market is anticipated to grow at a significant CAGR of 15.4% during the forecast period (2024-2031). The rising incidence of ovarian cancer globally is driving the growth of the global ovarian cancer drugs market. The advancements in drug development, personalized medicine, improved diagnostic techniques, awareness, government support, and technological innovations are key factors driving market growth and improving treatment outcomes.
Get Sample Copy of this Report at
https://www.omrglobal.com/request-sample/ovarian-cancer-drugs-market-size
global ovarian cancer drugs market dynamics
Market Dynamics
Rising Incidence and Prevalence
The global rise in ovarian cancer cases, particularly in elderly individuals, is driving demand for effective treatments and driving market growth. According to, the American Cancer Society, in January 2024, estimates for ovarian cancer in the US 2024, that approximately 19,680 individuals will receive a new diagnosis of ovarian cancer, and about 12,740 ovarian cancers predominantly affect elderly individuals, with half diagnosed at 63 years old, and is more frequently diagnosed in Whites than in Blacks.
Growing Awareness and Demand for Personalized Treatments
The growing awareness of personalized medicine benefits is driving demand for genomic testing and tailored therapies, contributing to the growth of the ovarian cancer drugs market. For instance, in June 2023, USask launched a clinical trial to improve ovarian cancer treatment, aiming to enhance quality of life and reduce costs. The trial combined multiple tumor test methods, providing patients with personalized genomic information about their tumors, enabling informed care choices and drug benefit estimates.
by Drug Class (PARP Inhibitors, Angiogenesis Inhibitors, and PD-L1 Inhibitors), and
by Therapy (Chemotherapy, Targeted Therapy, Immunotherapy, and Others)
Market Segmentation
Based on the drug class, the market is segmented into PARP Inhibitors, angiogenesis inhibitors, and PD-L1 inhibitors.
Based on the therapy, the market is segmented into chemotherapy, targeted therapy, immunotherapy, and others (hormonal therapy).
Chemotherapy is Projected to Hold the Largest Segment
The combination treatments, such as angiogenesis inhibitors, PD-L1 inhibitors, PARP inhibitors, and chemotherapy, have enhanced efficacy in clinical trials, changing therapeutic paradigms and driving market growth. For instance, in April 2023, a DUO-O Phase III trial showed that a combination of Lynparza and Imfinzi improved progression-free survival in patients with advanced ovarian cancer without tumor BRCA mutations. The treatment, which included Imfinzi, chemotherapy, and bevacizumab, showed a significant improvement in PFS compared to the control arm.
The major companies serving the global ovarian cancer drugs market include AstraZeneca, F. Hoffmann-La Roche Ltd, Merck Group, Eli Lilly and Co., and copyright Inc. among others. The market players are increasingly focusing on business expansion and product development by applying strategies such as collaborations, mergers and acquisitions to stay competitive in the market.
Recent Developments
In July 2024, Anixa Biosciences received FDA approval for a second dose of its ovarian cancer CAR-T therapy, following positive results in a patient from the lowest dose cohort. The Phase I clinical trial at Moffitt Cancer Center is treating recurrent ovarian cancer patients who have failed standard therapies.
In October 2023, Daiichi Sankyo and Merck signed a global development and commercialization agreement for three of Daiichi Sankyo's DXd antibody-drug conjugate candidates: patritumab deruxtecan (HER3-DXd), ifinatamab deruxtecan (I-DXd), and raludotatug deruxtecan (R-DXd). The candidates are in clinical development for multiple solid tumor treatments. Patritumab deruxtecan, granted Breakthrough Therapy.
The Report Covers
Market value data analysis of 2023 and forecast to 2031.
Annualized market revenues ($ million) for each market segment.
Country-wise analysis of major geographical regions.
Key companies operating in the global ovarian cancer drugs market. Based on the availability of data, information related to new products, and relevant news is also available in the report.
Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
Analysis of market-entry and market expansion strategies.
Competitive strategies by identifying ‘who-stands-where’ in the market.
Inquire for Discount on this Report at
https://www.omrglobal.com/report-customization/ovarian-cancer-drugs-market-size
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services. The company also offers Digital Marketing services through its subsidiary OMR Digital and Software development and Consulting Services through another subsidiary Encanto Technologies.
Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: [email protected]
Contact no: +91 780-304-0404